Prudentia Sciences is building the drug asset marketplace of the future by empowering biopharma to accelerate drug pipelines, maximize return on investment, and achieve clinical and commercial success for greater patient impact. The company also enables investors and biopharma to effectively position and showcase asset value during portfolio strategy planning and dealmaking, and equips investors with data-driven insights to optimize capital allocation in drug asset transactions.

The Prudentia Platform enables AI-powered Asset Diligence and Valuation to de-risk investment in drug development. Key capabilities include real-time data-driven simulation and scenario planning to optimize asset valuation for deal terms and speed to decision, rapid AI-powered synthesis of data room into asset assessment frameworks and product profiles to determine asset risks and value drivers, AI-guided product profiles and asset valuations to guide portfolio strategy and decision-making, and multi-disciplinary expert in-the-loop deal analysis and modeling with real-time analytics to enable AI-accelerated insight across multiple dimensions of asset value and risk.